stoxline Quote Chart Rank Option Currency Glossary
  
Ginkgo Bioworks Holdings, Inc. (DNA)
0.3702  0.034 (9.98%)    07-26 16:00
Open: 0.3343
High: 0.3789
Volume: 42,957,152
  
Pre. Close: 0.3366
Low: 0.3319
Market Cap: 823(M)
Technical analysis
2024-07-26 4:43:38 PM
Short term     
Mid term     
Targets 6-month :  0.53 1-year :  0.62
Resists First :  0.46 Second :  0.53
Pivot price 0.31
Supports First :  0.33 Second :  0.26
MAs MA(5) :  0.31 MA(20) :  0.32
MA(100) :  0.73 MA(250) :  1.25
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  59.1 D(3) :  38.5
RSI RSI(14): 51
52-week High :  2.51 Low :  0.26
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ DNA ] has closed above the upper band by 3.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 64.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 13 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.38 - 0.38 0.38 - 0.38
Low: 0.33 - 0.33 0.33 - 0.33
Close: 0.37 - 0.37 0.37 - 0.37
Company Description

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Headline News

Fri, 26 Jul 2024
Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards? - Zacks Investment Research

Thu, 25 Jul 2024
Ginkgo Bioworks (NYSE:DNA) Shares Gap Down to $0.30 - MarketBeat

Wed, 24 Jul 2024
Why the Market Dipped But Ginkgo Bioworks Holdings, Inc. (DNA) Gained Today - Yahoo Finance

Wed, 24 Jul 2024
Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) recent 14% pullback adds to one-year year losses, institutional owners may take drastic measures - Simply Wall St

Tue, 23 Jul 2024
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) - Longview News-Journal

Sun, 21 Jul 2024
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know - MSN

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 1,730 (M)
Shares Float 1,340 (M)
Held by Insiders 6.4 (%)
Held by Institutions 75.7 (%)
Shares Short 121,100 (K)
Shares Short P.Month 245,410 (K)
Stock Financials
EPS -0.44
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.46
Profit Margin 0 %
Operating Margin -469.2 %
Return on Assets (ttm) -21.8 %
Return on Equity (ttm) -65.9 %
Qtrly Rev. Growth -53 %
Gross Profit (p.s.) 0
Sales Per Share 0.12
EBITDA (p.s.) -0.37
Qtrly Earnings Growth 0 %
Operating Cash Flow -294 (M)
Levered Free Cash Flow -159 (M)
Stock Valuations
PE Ratio -0.87
PEG Ratio -0.1
Price to Book value 0.8
Price to Sales 3.06
Price to Cash Flow -2.18
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android